Details of study data collection
| Study procedure | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
|---|---|---|---|---|
| Informed consent | X | |||
| Demographics | X | |||
| Medical history | X | |||
| Inclusion and exclusion criteria | X | |||
| Current medications | X | |||
| Physical examination | X | X | ||
| X | X | X | X | |
| AQLQ | X | X | X | X |
| ACT | X | X | X | X |
| Randomisation | X | |||
| Dispense adapted Seretide inhaler | X | X | X | |
| Dispense electronic PEFR monitor | X | X | X | |
| Download device readings active only | X | X | X | |
| Inhaler use education | X | X | X | X |
| Adverse events recorded | X | X | X | |
| Concomitant medications recorded | X | X | X |
The active group receive a copy of device readings and active feedback about adherence and inhaler technique, visit 1: screening visit: at time of enrolment (week 0); visit 2: at end of month 1 (week 4); visit 3: at end of month 2 (week 8); visit 4: final visit at the end of month 3 (week 12).
AQLQ, Asthma Quality of Life Questionnaire; ACT, Asthma Control Test; PEFR, peak expiratory flow rate.